The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?
作者： Ahmed Selim , Ronald Zolty , Yiannis S. Chatzizisis
DOI: 10.1016/J.PHARMTHERA.2017.03.011
关键词: Pharmacotherapy 、 Clinical trial 、 Ejection fraction 、 Heart failure 、 Quality of life 、 In patient 、 Internal medicine 、 Treatment targets 、 Cardiology 、 Randomized controlled trial 、 Medicine 、 Pharmacology (medical) 、 Pharmacology
摘要: Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability the heart to meet body's needs, is end point for many other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at discovery treatments improve survival quality life patients with failure; were successful, while others failed. Given that most successes in treating failure achieved reduced left ventricular ejection fraction (HFrEF), we constructed this review look recent evolution HFrEF pharmacotherapy. We also explore some ongoing clinical trials new drugs, investigate potential treatment targets pathways might play role future.
elsevier.com
sci-hub.se 参考文章(201)
M A Pfeffer, The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz. ,vol. 1, pp. 430- 435 ,(1993)
Etienne Delacrétaz, Supraventricular Tachycardia New England Journal of Medicine. ,vol. 354, pp. 1039- 1051 ,(2006) , 10.1056/NEJMCP051145
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) The Lancet. ,vol. 353, pp. 2001- 2007 ,(1999) , 10.1016/S0140-6736(99)04440-2
G Michael Felker, Raymond L Benza, A Bleakley Chandler, Jeffrey D Leimberger, Michael S Cuffe, Robert M Califf, Mihai Gheorghiade, Christopher M O’Connor, OPTIME-CHF Investigators, None, Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. Journal of the American College of Cardiology. ,vol. 41, pp. 997- 1003 ,(2003) , 10.1016/S0735-1097(02)02968-6
Lincoln R. Potter, Andrea R. Yoder, Darcy R. Flora, Laura K. Antos, Deborah M. Dickey, Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handbook of experimental pharmacology. pp. 341- 366 ,(2009) , 10.1007/978-3-540-68964-5_15
Luisa Mestroni, Matthew R G Taylor, Pharmacogenomics, personalized medicine, and heart failure. Discovery Medicine. ,vol. 11, pp. 551- 561 ,(2011)
W. Y. Wandy Chan, Christopher M. Frampton, Ian G. Crozier, Richard W. Troughton, A. Mark Richards, Urocortin-2 Infusion in Acute Decompensated Heart Failure: Findings From the UNICORN Study (Urocortin-2 in the Treatment of Acute Heart Failure as an Adjunct Over Conventional Therapy) Jacc-Heart Failure. ,vol. 1, pp. 433- 441 ,(2013) , 10.1016/J.JCHF.2013.07.003
Sharon Ann Hunt, None, ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. ,vol. 46, pp. 1116- 1143 ,(2005) , 10.1016/J.JACC.2005.08.022
Ashok Krishnaswami, The Role of B-Type and Other Natriuretic Peptides in Health and Disease The Permanente Journal. ,vol. 12, pp. 32- 43 ,(2008) , 10.7812/TPP/08-019
Xiao-Chen Wang, Dong-Min Zhu, Yu-Xuan Shan, Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis American Journal of Cardiovascular Drugs. ,vol. 15, pp. 429- 437 ,(2015) , 10.1007/S40256-015-0134-3